Clinical data | |
---|---|
Trade names | Bonine, Antivert, others |
Other names | Meclozine |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682548 |
License data | |
Routes of administration | By mouth, under the tongue, in the cheek |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 22 - 32%[1] |
Metabolism | Liver (CYP2D6) |
Elimination half-life | 5-6 hours[2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.008.477 |
Chemical and physical data | |
Formula | C25H27ClN2 |
Molar mass | 390.96 g·mol−1 |
3D model (JSmol) | |
Boiling point | 230 °C (446 °F) |
| |
| |
(what is this?) (verify) |
Meclizine, sold under the brand name Bonine, among others, is an antihistamine used to treat motion sickness and dizziness (vertigo).[3] It is taken by mouth.[3] Effects generally begin in an hour and last for up to a day.[3]
Common side effects include sleepiness and dry mouth.[3] Serious side effects may include allergic reactions.[3] Use in pregnancy appears safe, but has not been well studied; use in breastfeeding is of unclear safety.[4] It is believed to work in part by anticholinergic and antihistamine mechanisms.[3]
Meclizine was patented in 1951 and came into medical use in 1953.[5] It is available as a generic medication and often over the counter.[3][6] In 2022, it was the 129th most commonly prescribed medication in the United States, with more than 4 million prescriptions.[7][8]